Sep 14, 2026 7:00am EDT Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Sep 03, 2026 4:05pm EDT Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Jul 21, 2026 7:00am EDT Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Jul 08, 2026 7:02am EDT Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Jun 30, 2026 7:00am EDT Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Jun 16, 2026 7:00am EDT Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Jun 15, 2026 7:02am EDT Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Jun 02, 2026 7:02am EDT Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
May 04, 2026 7:01am EDT Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Apr 20, 2026 7:01am EDT Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
